Literature DB >> 31092416

NEK2 Is an Effective Target for Cancer Therapy With Potential to Induce Regression of Multiple Human Malignancies.

Toshio Kokuryo1, Yukihiro Yokoyama2, Junpei Yamaguchi2, Nobuyuki Tsunoda2, Tomoki Ebata2, Masato Nagino2.   

Abstract

Cancer is characterized by uncontrolled cell proliferation due to the aberrant activity of various proteins. Cell cycle-related proteins are thought to be important in several functions, such as proliferation, invasion and drug resistance in human malignancies. Never in mitosis gene A-related kinase 2 (NEK2) is a cell cycle-related protein. NEK2 is highly expressed in various tumor types and cancer cell lines. NEK2 expression is correlated with rapid relapse and poor outcome in multiple cancer types. Several researchers have demonstrated that NEK2 inhibition results in anticancer effects against many types of cancers, both in vitro and in vivo. Recent research strongly indicates the advantages of NEK2-targeted therapy for cancer. This review focuses on the current understanding of NEK2 in cancer and the rationale of a xenograft cancer model for cancer treatment. A possible therapeutic strategy, such as inhibitor and nucleic acid medicine targeting of NEK2, is also discussed. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Drug delivery system; Inhibitor; NEK2; nucleic acid medicine; review; xenograft cancer model

Mesh:

Substances:

Year:  2019        PMID: 31092416     DOI: 10.21873/anticanres.13341

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

Review 1.  Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.

Authors:  Silvia Uccella; Stefano La Rosa; Jasna Metovic; Deborah Marchiori; Jean-Yves Scoazec; Marco Volante; Ozgur Mete; Mauro Papotti
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 2.  The NEK family of serine/threonine kinases as a biomarker for cancer.

Authors:  Nagesh Kishan Panchal; Sabina Evan Prince
Journal:  Clin Exp Med       Date:  2022-01-17       Impact factor: 3.984

Review 3.  The emerging roles and potential applications of circular RNAs in ovarian cancer: a comprehensive review.

Authors:  Sajad Najafi
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-02       Impact factor: 4.322

4.  High expression of NEK2 promotes gastric cancer progression via activating AKT signaling.

Authors:  Hao Wan; Lin Xu; Huangbin Zhang; Feixiang Wu; Weiqiang Zeng; Taiyuan Li
Journal:  J Physiol Biochem       Date:  2020-11-17       Impact factor: 4.158

5.  Silencing of Nek2 suppresses the proliferation, migration and invasion and induces apoptosis of breast cancer cells by regulating ERK/MAPK signaling.

Authors:  Zeyu Xing; Menglu Zhang; Xin Wang; Jiaqi Liu; Gang Liu; Kexin Feng; Xiang Wang
Journal:  J Mol Histol       Date:  2021-05-19       Impact factor: 2.611

6.  High Expression of NEK2 and PIM1, but Not PIM3, Is Linked to an Aggressive Phenotype of Bronchopulmonary Neuroendocrine Neoplasms.

Authors:  Ewelina Motylewska; Marcin Braun; Henryk Stępień
Journal:  Endocr Pathol       Date:  2020-09       Impact factor: 3.943

7.  Targeting NEK2 impairs oncogenesis and radioresistance via inhibiting the Wnt1/β-catenin signaling pathway in cervical cancer.

Authors:  Tie Xu; Yulan Zeng; Linli Shi; Qin Yang; Yeshan Chen; Gang Wu; Guiling Li; Shuangbing Xu
Journal:  J Exp Clin Cancer Res       Date:  2020-09-10

Review 8.  On Broken Ne(c)ks and Broken DNA: The Role of Human NEKs in the DNA Damage Response.

Authors:  Isadora Carolina Betim Pavan; Andressa Peres de Oliveira; Pedro Rafael Firmino Dias; Fernanda Luisa Basei; Luidy Kazuo Issayama; Camila de Castro Ferezin; Fernando Riback Silva; Ana Luisa Rodrigues de Oliveira; Lívia Alves Dos Reis Moura; Mariana Bonjiorno Martins; Fernando Moreira Simabuco; Jörg Kobarg
Journal:  Cells       Date:  2021-02-27       Impact factor: 6.600

9.  Up to your NEK2 in CIN.

Authors:  Darcie D Seachrist; Lindsey J Anstine; Ruth A Keri
Journal:  Oncotarget       Date:  2021-04-13

10.  A Transcriptome-Wide Isoform Landscape of Melanocytic Nevi and Primary Melanomas Identifies Gene Isoforms Associated with Malignancy.

Authors:  Siras Hakobyan; Henry Loeffler-Wirth; Arsen Arakelyan; Hans Binder; Manfred Kunz
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.